Robert Pelham
About Robert Pelham
Robert Pelham is the Director of Biomarkers and Companion Diagnostics at BeiGene, with extensive experience in the biotech industry in the San Francisco Bay Area.
Current Role at BeiGene
Robert Pelham is currently serving as the Director of Biomarkers and Companion Diagnostics at BeiGene. He has been leading the division since January 2018. His role primarily involves overseeing the development and implementation of biomarker strategies that help in the diagnosis and treatment of cancer. Located in the San Francisco Bay Area, BeiGene is focused on developing molecularly targeted and immuno-oncology drug candidates.
Previous Experience at Amgen
Before joining BeiGene, Robert Pelham worked at Amgen as a Principal Scientist and Therapeutic Area Lead from 2015 to 2018. During his tenure, he led significant initiatives in scientific research and development, contributing to therapeutic advancements. Amgen is a leading biotechnology firm known for innovating drugs aimed at serious illnesses.
Background in Oncology Product Development at Natera
Robert Pelham also has experience in oncology product development, having worked at Natera as the Director of Oncology Product Development from 2014 to 2015. In this role, he was responsible for guiding the development of cancer diagnostics products. Natera is well-regarded for its expertise in cell-free DNA testing and genetic diagnostics.
Research and Development Experience at Genomic Health
From 2007 to 2014, Robert Pelham worked at Genomic Health, first as a Scientist and later as a Senior Scientist. Over these seven years, he contributed to various research projects aimed at improving cancer treatment through genomic technologies. Genomic Health is focused on genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer.
Academic Achievements and Postdoctoral Fellowship
Robert Pelham holds a Ph.D. in Genetics and Cell Biology from Columbia University College of Physicians and Surgeons, earned between 1998 and 2003. He also completed a Postdoctoral Fellowship at Princeton University from 2003 to 2007. His undergraduate education includes a Bachelor of Arts in Politics and Biology from Brandeis University, completed between 1990 and 1994. His academic background has greatly contributed to his expertise and success in the biotechnology industry.